- Boston Scientific Completes Acquisition of Bolt Medical, Bolstering Cardiovascular Portfolio
- Two Property Multifamily Portfolio For Sale in Naples, Florida
- 3 Dividend Stocks Offering Yields Up To 9.8% For Your Income Portfolio
- Nancy Pelosi’s Portfolio Beats Top Hedge Funds With 54% Gains in 2024
- Why You Should Hold Waste Management Stock in Your Portfolio Now
In recent weeks, global markets have seen a mix of economic signals, with major stock indexes mostly declining except for the Nasdaq Composite, which reached a record high. This comes amid expectations of further interest rate cuts by central banks and signs of a cooling labor market in the U.S., creating an environment where growth stocks continue to outperform value stocks. In such conditions, identifying high-growth tech stocks can be crucial for investors seeking to capitalize on sectors showing resilience and potential despite broader market challenges.
Bạn đang xem: Exploring None And 2 Other High Growth Tech Stocks For Your Portfolio
Name |
Revenue Growth |
Earnings Growth |
Growth Rating |
---|---|---|---|
Material Group |
20.45% |
24.01% |
★★★★★★ |
Seojin SystemLtd |
35.41% |
39.86% |
★★★★★★ |
Yggdrazil Group |
30.20% |
87.10% |
★★★★★★ |
eWeLLLtd |
27.24% |
28.74% |
★★★★★★ |
Medley |
25.57% |
31.67% |
★★★★★★ |
Mental Health TechnologiesLtd |
25.83% |
113.12% |
★★★★★★ |
Fine M-TecLTD |
36.52% |
131.08% |
★★★★★★ |
Initiator Pharma |
73.95% |
31.67% |
★★★★★★ |
Elliptic Laboratories |
70.09% |
111.37% |
★★★★★★ |
JNTC |
29.48% |
104.37% |
★★★★★★ |
Click here to see the full list of 1262 stocks from our High Growth Tech and AI Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Hugel, Inc. is a company that develops and manufactures biopharmaceuticals in South Korea and internationally, with a market cap of ₩2.97 trillion.
Operations: The company generates revenue primarily from its pharmaceuticals segment, amounting to ₩363.79 billion.
Hugel, recently active in share repurchases, has demonstrated robust financial health with a 42.7% earnings growth surpassing its industry’s 5.8%. The company’s commitment to innovation is evident from its R&D investments, aligning with an aggressive growth trajectory in earnings and revenue projected at 22% and 17.3% annually, outpacing the KR market averages of 12.3% and 5.3%, respectively. This performance is further bolstered by strategic partnerships like the extended distribution agreement with Sihuan Pharmaceutical for Letybo in China, ensuring sustained market penetration and dominance in key international markets.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: NEXON Games Co., Ltd. is a South Korean game developer with international operations and a market cap of approximately ₩898.13 billion.
Operations: The company generates revenue primarily through game sales, amounting to approximately ₩245.04 billion. Other sales contribute a smaller portion of the revenue stream.
Nguồn: https://earnestmoney.skin
Danh mục: News